ATRX and neuroblastoma: Consistent with these findings, high-throughput compound screening showed the preclinical sensitivity of combination therapy with olaparib (a PARP inhibitor)/irinotecan (a DNA-damaging agent) in NB models with genetic alterations in ATRX, which may be rapidly translated into clinical settings [104].